RahulAggarwalMD

Oncology • San Francisco, CA

Assistant Professor of Hematology/Oncology, Director of STAND Clinic, UCSF

Join to view full profile

Dr. Aggarwal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Aggarwal's full profile

Already have an account?

Office
505 Parnassus Ave
Room M987
San Francisco, CA 94143
Phone+1 415-476-1000
Is this information wrong?

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2010 - 2013
University of California (San Francisco)Residency, Internal Medicine, 2006 - 2009
Northwestern University The Feinberg School of MedicineClass of 2006

Certifications & Licensure

CA State Medical License 2008 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 1
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer Start of enrollment: 2013 Oct 29
Completed
Phase 2
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer Start of enrollment: 2014 Jun 16
Terminated
Phase 2
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2014 Sep 02
Terminated
Phase 2
MRI With C13 Pilot Study Prostate Cancer Start of enrollment: 2016 Oct 12
Terminated
Early Phase 1
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC Start of enrollment: 2015 Nov 20
Completed
Phase 1, Phase 2
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer Start of enrollment: 2016 Mar 22
Recruiting
Early Phase 1
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. Start of enrollment: 2019 Feb 12
Active, not recruiting
Phase 1, Phase 2
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2021 Sep 28
Active, not recruiting
Phase 2
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) Start of enrollment: 2018 Jul 17
Recruiting
Phase 3
Roles: Contact, Study Chair
Join now to see all

Publications & Presentations

PubMed

Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer.
Hewitt Chang, Jaqueline Marquez, Brandon K Chen, Daniel M Kim, Michael L Cheng, Eric V Liu, Hai Yang, Li Zhang, Meenal Sinha, Alexander Cheung, Serena S Kwek, Eric D C...> ;Cancer Immunology Research. 2024 Apr 2
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Wise, D., Pachynski, R., Denmeade, S., Aggarwal, R., Deng, J., Febles, V., Balar, A., Economides, M., Loomis, C., Selvaraj, S., Haas, M., Kagey, M., Newman, W., Baum, ...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 10
Biomarkers and novel PET imaging to detect neuroendocrine prostate cancer.
Aggarwal, R.> ;Clinical Advances in Hematology & Oncology. 2024 Jan 31
Initial Experience withGa-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
Kline, B., Aslam, M., de Kouchkovsky, I., Koshkin, V., Kumar, V., Escobar, D., Cooperberg, M., Aggarwal, R., Chou, J., Meng, M., Friedlander, T., Porten, S., Hope, T.> ;Journal of Nuclear Medicine. 2024 Feb 1
Diagnosis and management of neuroendocrine prostate cancer.
de Kouchkovsky, I., Chan, E., Schloss, C., Poehlein, C., Aggarwal, R.> ;The Prostate. 2024 Apr 1
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Lalji, A., Mark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, Laura A Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria Sinibaldi, Michael A Carducci, Channing J Pall...> ;Nature Communications. 2024 Jan 2
Development of CD46 targeted alpha theranostics in prostate cancer usingCe/Ac-Macropa-PEG-YS5.
Bobba, K., Bidkar, A., Wadhwa, A., Meher, N., Drona, S., Sorlin, A., Bidlingmaier, S., Zhang, L., Wilson, D., Chan, E., Greenland, N., Aggarwal, R., VanBrocklin, H., H...> ;Theranostics. 2024 Jan 1
1 citations
Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer.
Chitra Priya Emperumal, Alessandro Villa, Caleb Hwang, David Oh, Lawrence Fong, Rahul Aggarwal, Bridget P Keenan> ;Clinical Genitourinary Cancer. 2024 Apr 1
A case of cetuximab-induced radiation recall skin dermatitis and review of the literature.
Sabol, R., Patel, A., Sabbagh, A., Wilson, C., Yuen, F., Lindenfeld, P., Aggarwal, R., Breyer, B., Mohamad, O.> ;Radiation Oncology Journal. 2023 Dec 1
1 citations
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Jimmy L Zhao, Emmanuel S Antonarakis, Heather H Cheng, Daniel J George, Rahul Aggarwal, Elyn Riedel, Takayuki Sumiyoshi, Joseph D Schonhoft, Amanda Anderson, Ninghui M...> ;British Journal of Cancer. 2024 Jan 1
2 citations
Single-doseLu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 t...
Rahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, Vadim Koshkin, Rohit Bose, Jonathan Chou, Arpita Desai, Daniel Kwon, Samuel Kaushal, Lauren Trihy, Medini Ra...> ;The Lancet. Oncology. 2023 Nov 1
4 citations
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
Arian Lundberg, Meng Zhang, Rahul Aggarwal, Haolong Li, Li Zhang, Adam Foye, Martin Sjöström, Jonathan Chou, Kevin Chang, Thaidy Moreno-Rodriguez, Raunak Shrestha, Avi...> ;Cancer Research. 2023 Aug 15
1 citations
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfo...
Tanya Jindal, Li Zhang, Prianka Deshmukh, Kevin Reyes, Emily Chan, Vipul Kumar, Xiaolin Zhu, Edward Maldonado, Stephanie Feng, Michelle Johnson, Austin Angelidakis, Da...> ;Clinical Genitourinary Cancer. 2023 Oct 1
7 citations
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy.
Anil P Bidkar, Sinan Wang, Kondapa Naidu Bobba, Emily Chan, Scott Bidlingmaier, Emily A Egusa, Robin Peter, Umama Ali, Niranjan Meher, Anju Wadhwa, Suchi Dhrona, Chand...> ;Clinical Cancer Research. 2023 May 15
Enrollment Barriers for Molecular Targeted Trials.
Koosha Paydary, Alli DeLuca, Rahul Aggarwal, Lauren Wall, Walter M Stadler> ;JAMA Oncology. 2023 Jun 1
6 citations
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer.
Emerson A Lim, Michael T Schweizer, Kim N Chi, Rahul Aggarwal, Neeraj Agarwal, James Gulley, Edward Attiyeh, James Greger, Shujian Wu, Pharavee Jaiprasart, John Loffre...> ;Clinical Genitourinary Cancer. 2023 Jun 1
Intermittent Hormonal Therapy in Biochemical Recurrence of Prostate Cancer Is Worth Considering Because of Mitigation of Cardiovascular Events and Reduction of Other E...
Daniel H Kwon, Rahul R Aggarwal> ;European Urology Focus. 2023 May 1
6 citations
Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer.
Daniel H Kwon, Kelly M Gordon, Barry Tong, Hala T Borno, Makenna Beigh, Delaire Fattah, Alexandra Schleicher, Rahul R Aggarwal, Amie M Blanco, Eric J Small, Dhawan, M....> ;JCO Oncology Practice. 2023 May 1
1 citations
Somatic alterations ofandassociated with response to enfortumab vedotin in patients with advanced urothelial cancer.
Tanya Jindal, Xiaolin Zhu, Rohit Bose, Vipul Kumar, Edward Maldonado, Prianka Deshmukh, Chase Shipp, Stephanie Feng, Michelle S Johnson, Austin Angelidakis, Daniel Kwo...> ;Frontiers in Oncology. 2023 Jan 1
2 citations
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention.
Crystal S Langlais, Yea-Hung Chen, Erin L Van Blarigan, June M Chan, Charles J Ryan, Li Zhang, Hala T Borno, Robert U Newton, Anthony Luke, Alexander S Bang, Neil Panc...> ;Urologic Oncology. 2023 Mar 1
1 citations
Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
Daniel H Kwon, Nonna Shakhnazaryan, David Shui, Julian C Hong, Osama Mohamad, Ivan de Kouchkovsky, Hala T Borno, Rohit Bose, Jonathan Chou, Arpita Desai, Lawrence Fong...> ;Urologic Oncology. 2023 Mar 1
7 citations
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer.
Jonathan Chou, Emily A Egusa, Sinan Wang, Michelle L Badura, Fei Lee, Anil P Bidkar, Jun Zhu, Tanushree Shenoy, Kai Trepka, Troy M Robinson, Veronica Steri, Jiaoti Hua...> ;Cancer Research. 2023 Jan 18
3 citations
Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.
Eric Feng, Nicholas R Rydzewski, Meng Zhang, Arian Lundberg, Matthew Bootsma, Kyle T Helzer, Joshua M Lang, Rahul Aggarwal, Eric J Small, David A Quigley, Martin Sjöst...> ;Clinical Cancer Research. 2022 Dec 15
13 citations
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
Martin Sjöström, Shuang G Zhao, Samuel Levy, Meng Zhang, Yuhong Ning, Raunak Shrestha, Arian Lundberg, Cameron Herberts, Adam Foye, Rahul Aggarwal, Junjie T Hua, Haolo...> ;Cancer Research. 2022 Nov 2
9 citations
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
Thomas C Westbrook, Xiangnan Guan, Eva Rodansky, Diana Flores, Chia Jen Liu, Aaron M Udager, Radhika A Patel, Michael C Haffner, Ya-Mei Hu, Duanchen Sun, Tomasz M Beer...> ;Nature Communications. 2022 Sep 15
Join now to see all

Lectures

Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study.
2019 ASCO Annual Meeting - 6/1/2019
DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant pr...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Breaking the Boundaries Between Radiology and Oncology: GU Oncology Profiles Thomas a. Hope, MDApril 28th, 2022
Androgen Deprivation Therapy and SARS-CoV-2 in Men with Prostate Cancer: Findings from the University of California Health System RegistryFebruary 8th, 2021
Xynomic Pharma to Present Long-Term Follow up Data Showing Abexinostat, Combined with Pazopanib, Has Durable Responses in Patients with Pre-Treated Kidney CancerMay 21st, 2019
Join now to see all